Latest filing published 06 Feb 2025 for Verrica Pharmaceuticals Inc..
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Ted White (chief executive) discloses dealings in Verrica Pharmaceuticals Inc. to SEC (Form 4). Between 19 June 2018 and 27 August 2024, the trades on record add up to 19 filings.
In open-market terms, that means 8 purchases worth €251k on one side and 7 sales worth €604k on the other. On balance, insiders were net sellers of €354k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 4 share grants.
The median purchase comes to €29k. Clusters matter here: 8 out of 8 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
On 6 February 2025 came the latest disclosure, a share grant in Verrica Pharmaceuticals Inc. The most recent open-market purchase was published on 21 February 2023, 1,341 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 of 10 declarations